Loss of SUMOylation on ATF3 Inhibits Proliferation of Prostate Cancer Cells by Modulating CCND1/2 Activity
Open Access
- 16 April 2013
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (4) , 8367-8380
Abstract
SUMOylation plays an important role in regulating a wide range of cellular processes. Previously, we showed that ATF3, a stress response mediator, can be SUMOylated and lysine 42 is the major SUMO site. However, the significance of ATF3 SUMOylation in biological processes is still poorly understood. In the present study, we investigated the role of ATF3 SUMOylation on CCND activity and cellular proliferation in human prostate cancer cells. First, we showed that ATF3 can be SUMOylated endogenously in the overexpression system, and lysine 42 is the major SUMO site. Unlike normal prostate tissue and androgen-responsive LNCaP cancer cells, androgen-independent PC3 and DU145 cancer cells did not express ATF3 endogenously. Overexpression of ATF3 increased CCND1/2 expression in PC3 and DU145 cancer cells. Interestingly, we observed that SUMOylation is essential for ATF3-mediated CCND1/2 activation. Finally, we observed that SUMOylation plays a functional role in ATF3-mediated cellular proliferation in PC3 and DU145 cells. Taken together, our results demonstrate that SUMO modification of ATF3 influences CCND1/2 activity and cellular proliferation of prostate cancer PC3 and DU145 cells and explains at least in part how ATF3 functions to regulate cancer development.Keywords
This publication has 46 references indexed in Scilit:
- Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions.2013
- Metabolic Complications of Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2013
- Androgen Deprivation Therapy in Advanced Prostate Cancer: Is Intermittent Therapy the New Standard of Care?Current Oncology, 2012
- Feedback regulation by Atf3 in the endothelin-1-responsive transcriptome of cardiomyocytes: Egr1 is a principal Atf3 targetBiochemical Journal, 2012
- Activation of the Canonical Wnt/β-Catenin Pathway in ATF3-Induced Mammary TumorsPLOS ONE, 2011
- Activating Transcription Factor 3 Activates p53 by Preventing E6-associated Protein from Binding to E6Journal of Biological Chemistry, 2010
- A potential dichotomous role of ATF3, an adaptive-response gene, in cancer developmentOncogene, 2007
- Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitinationThe EMBO Journal, 2005
- A Self-Enabling TGFβ Response Coupled to Stress SignalingMolecular Cell, 2003
- gadd153/Chop10 , a Potential Target Gene of the Transcriptional Repressor ATF3Molecular and Cellular Biology, 1997